Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Plant Dis ; 2024 Jun 20.
Artigo em Inglês | MEDLINE | ID: mdl-38902883

RESUMO

The Fusarium head blight (FHB) caused by Fusarium graminearum is a serious fungal disease that can dramatically impact wheat production. At present, control is mainly achieved by the use of chemical fungicides. Hexaconazole (IUPAC name: 2-(2,4-dichlorophenyl)-1-(1,2,4-triazol-1-yl)hexan-2-ol) is a widely used triazole fungicide, but the sensitivity of F. graminearum to this compound has yet to be established. The current study found that the EC50 values of 83 field isolates of F. graminearum ranged between 0.06 and 4.33 µg/mL, with an average EC50 of 0.78 µg/mL. Assessment of four hexaconazole-resistant laboratory mutants of F. graminearum revealed that their mycelial growth, and pathogenicity were reduced compared to their parental isolates, and that asexual reproduction was reduced by resistance to hexaconazole. Meanwhile, the mutants appeared to be more sensitive to abiotic stress associated with SDS, and H2O2, while their tolerance of high concentration of Congo red, and Na+ and K+ increased. Molecular analysis revealed numerous point mutations in the FgCYP51 target genes that resulted in amino acid substitutions, including L92P and N123S in FgCYP51A, as well as M331V, F62L, Q252R, A412V, and V488A in FgCYP51B, and S28L, S256A, V307A, D287G and R515I in FgCYP51C, three of which (S28L, S256A, and V307A) were conserved in all of the resistant mutants. Furthermore, the expression of the FgCYP51 genes in resistant strains was found to be significantly (p < 0.05) reduced compared to their sensitive parental isolates. Positive cross-resistance was found between hexaconazole and metconazole and flutriafol, as well as with the diarylamine fungicide fluazinam, but not with propiconazole, and the phenylpyrrole fungicide fludioxonil, or with tebuconazole, which actually exhibited negative cross-resistance. These results provide valuable insight into resistant mechanisms to triazole fungicides in F. graminearum, as well as the appropriate selection of fungicide combinations for the control of FHB to ensure optimal wheat production.

2.
Neoplasma ; 70(2): 272-286, 2023 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-37226932

RESUMO

Nuclear ubiquitous casein and cyclin-dependent kinase substrate 1 (NUCKS1) is highly expressed in a variety of malignant tumors and functions as an oncogene; however, its role in colorectal cancer (CRC) remains unclear. We aimed to explore the function and regulatory mechanisms of NUCKS1 and potential therapeutic agents targeting NUCKS1 in CRC. We knocked down and overexpressed NUCKS1 in CRC cells and explored its effects in vitro and in vivo. Flow cytometry, CCK-8, Western blotting, colony formation, immunohistochemistry, in vivo tumorigenic, and transmission electron microscopy analyses were performed to determine the effects of NUCKS1 on CRC cell function. LY294002 was used to examine the mechanism of NUCKS1 expression in CRC cells. Potential therapeutic agents for NUCKS1-high CRC patients were analyzed using the CTRP and PRISM datasets, and the function of selected agents was determined by CCK-8 and Western blotting. We revealed that NUCKS1 was highly expressed in CRC tissues and clinically correlated with poor prognosis in CRC patients. NUCKS1 knockdown induces cell cycle arrest, inhibits CRC cell proliferation, and promotes apoptosis and autophagy. These results were reversed when NUCKS1 was overexpressed. Mechanistically, NUCKS1 exerts a cancer-promoting function by activating the PI3K/AKT/mTOR signaling pathway. This was reversed when LY294002 was used to inhibit the PI3K/AKT pathway. Furthermore, we determined that mitoxantrone exhibited high drug sensitivity in NUCKS1-overexpressing CRC cells. This work demonstrated NUCKS1 plays a crucial role in CRC progression via the PI3K/AKT/mTOR signaling pathway. Additionally, mitoxantrone may be a potential therapeutic agent for CRC treatment. Therefore, NUCKS1 represents a promising anti-tumor therapeutic target.


Assuntos
Neoplasias Colorretais , Proteínas Nucleares , Fosfatidilinositol 3-Quinases , Fosfoproteínas , Humanos , Neoplasias Colorretais/tratamento farmacológico , Neoplasias Colorretais/genética , Mitoxantrona , Proteínas Proto-Oncogênicas c-akt , Transdução de Sinais , Serina-Treonina Quinases TOR , Fosfoproteínas/genética , Fosfoproteínas/metabolismo , Proteínas Nucleares/genética , Proteínas Nucleares/metabolismo
3.
Cancer Chemother Pharmacol ; 91(2): 167-177, 2023 02.
Artigo em Inglês | MEDLINE | ID: mdl-36622402

RESUMO

PURPOSE: Colorectal cancer (CRC) is the second most common cause of cancer death worldwide. Trifluridine (FTD) remained at higher concentrations longer when administered along with tipiracil (TPI) compared with FTD alone. Lonsurf® is a combination formulation consisting of FTD and TPI. This study aimed to investigate the bioequivalence of FTD/TPI formulations in Chinese metastatic colorectal cancer (mCRC) patients. METHODS: In this phase I, randomized, open-label, single-dose, two-sequence, four-cycle crossover study in mCRC patients, the bioequivalence of 60 mg (20 mg tablet, 3 tablets) of the test formulation and the reference formulation (Lonsurf®) was evaluated. Due to its high variability, the method of reference-scaled average bioequivalence (RSABE) was used to investigate the bioequivalence of the test and reference formulations. RESULTS: Thirty-two patients were enrolled. 78.1% of the subjects were male, and the mean (standard deviation) age was 53.9 (SD = ± 9.0) years old. The time to reach the maximum plasma concentration (Tmax) was almost 2.0 h post-dose. The geometric least-squares mean ratios (GMRs) (test/reference) of Cmax and AUC0-t for FTD were 95.3% and 102.9%, respectively, with 90% confidence intervals (CIs) for the natural log-transformed ratios of Cmax and AUC0-t of 90.0-100.9% and 99.9-105.9%, while the GMRs of Cmax and AUC0-t for TPI were 95.7% and 100.7%, respectively, with 90% CIs of 90.5-101.2% and 97.0-104.7%. In addition, the GMRs of Cmax and AUC0-t for FTD's major metabolite, trifluorothymine (FTY), were 94.8 (90% CI 90.3-99.5%) and 99.33 (90% CI 96.9-101.9%), respectively. These were in accord with the FDA bioequivalence definition interval of 80-125%. CONCLUSION: The test and reference FTD/TPI formulations were bioequivalent in Chinese mCRC patients under fed conditions.


Assuntos
Neoplasias Colorretais , Trifluridina , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Área Sob a Curva , Neoplasias Colorretais/tratamento farmacológico , Estudos Cross-Over , População do Leste Asiático , Comprimidos , Equivalência Terapêutica , Trifluridina/farmacocinética , Combinação de Medicamentos , Adulto
4.
Mol Biol Rep ; 39(3): 3029-35, 2012 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-21678053

RESUMO

Bone is one of the most frequent targets of small cell lung cancer (SCLC) metastasis, but the molecular mechanism remains unclear. ß3-integrin plays an important role in invasion of various kinds of tumors. Yet, its role in bone-metastasis of SCLC is still unknown. In this study, we first examined the expression of ß3-integrin in SBC-5 and SBC-3 cells by real-time PCR, western blot and immunofluorescence. We found that, compared to none bone-metastatic SBC-3 cells, ß3-integrin was highly expressed in SBC-5 cells, a specific bone-metastatic SCLC cells line characterized in our previous study. We next constructed ß3-integrin siRNA and transfected SBC-5 cell line, and found that ß3-integrin siRNA significantly down-regulated the ß3-integrin mRNA level and protein expression in SBC-5 cell line. We further found that inhibition of ß3-integrin significantly reduced tumor cell proliferation and induced apoptosis. In addition, the ß3-integrin down-regulated cells presented significant decrease in cell adhesion, migration and invasion activity. Our results suggest the ß3-integrin has an essential effect on tumor cell proliferation and progression, and may be a potential therapeutic target for the prevention of skeletal metastases of lung cancer.


Assuntos
Neoplasias Ósseas/secundário , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Integrina beta3/metabolismo , Carcinoma de Pequenas Células do Pulmão/patologia , Apoptose/efeitos dos fármacos , Western Blotting , Neoplasias Ósseas/genética , Neoplasias Ósseas/metabolismo , Linhagem Celular Tumoral , Movimento Celular/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Colágeno , Ensaio de Unidades Formadoras de Colônias , Combinação de Medicamentos , Citometria de Fluxo , Imunofluorescência , Humanos , Integrina beta3/genética , Laminina , Proteoglicanas , RNA Interferente Pequeno/genética , RNA Interferente Pequeno/metabolismo , RNA Interferente Pequeno/farmacologia , Reação em Cadeia da Polimerase em Tempo Real , Carcinoma de Pequenas Células do Pulmão/genética , Carcinoma de Pequenas Células do Pulmão/metabolismo , Sais de Tetrazólio , Tiazóis
5.
J Fungi (Basel) ; 8(8)2022 Aug 11.
Artigo em Inglês | MEDLINE | ID: mdl-36012827

RESUMO

Melon Fusarium wilt (MFW), which is caused by Fusarium oxysporum f. sp. melonis (FOM), is a soil-borne disease that commonly impacts melon cultivation worldwide. In the absence of any disease-resistant melon cultivars, the control of MFW relies heavily on the application of chemical fungicides. Fludioxonil, a phenylpyrrole fungicide, has been shown to have broad-spectrum activity against many crop pathogens. Sensitivity analysis experiments suggest that fludioxonil has a strong inhibitory effect on the mycelial growth of FOM isolates. Five fludioxonil-resistant FOM mutants were successfully generated by repeated exposure to fludioxonil under laboratory conditions. Although the mutants exhibited significantly reduced mycelial growth in the presence of the fungicide, there initially appeared to be little fitness cost, with no significant difference (p < 0.05) in the growth rates of the mutants and wild-type isolates. However, further investigation revealed that the sporulation of the fludioxonil-resistant mutants was affected, and mutants exhibited significantly (p < 0.05) reduced growth rates in response to KCl, NaCl, glucose, and mannitol. Meanwhile, molecular analysis of the mutants strongly suggested that the observed fludioxonil resistance was related to changes in the sequence and expression of the FoOs1 gene. In addition, the current study found no evidence of cross-resistance between fludioxonil and any of the other fungicides tested. These results indicate that fludioxonil has great potential as an alternative method of control for FOM in melon crops.

6.
Neurosci Lett ; 541: 275-80, 2013 Apr 29.
Artigo em Inglês | MEDLINE | ID: mdl-23415758

RESUMO

Tumor necrosis factor alpha (TNF-α) is known for its role in inflammation and pain, which are strongly associated with mood disorders such as anxiety and depression. The amygdala is a forebrain structure that modulates anxiety. However, little is known about the role of TNF-α in the development of anxiety in animals with chronic pain. In the present study, we examined TNF-α expression in the basolateral amygdala (BLA) following injection of complete Freund's adjuvant (CFA) into the hind paw of mice to induce inflammation. We also determined the effects of TNF-α expression on the development of anxiety in these mice. TNF-α expression was increased in the BLA during the chronic phase of CFA-induced peripheral inflammation. The local infusion of TNF-α-neutralizing antibody infliximab in the BLA reversed anxiety-like behaviors in mice with persistent inflammatory pain. In vitro slice recordings revealed that TNF-α significantly enhanced AMPA-receptor-mediated glutamatergic excitatory synaptic transmission and inhibited GABAA-receptor-mediated inhibitory synaptic transmission in the BLA. Our findings, therefore, provide strong evidence that TNF-α contributes to the development of anxiety in mice with persistent inflammatory pain.


Assuntos
Tonsila do Cerebelo/metabolismo , Ansiedade/psicologia , Dor Crônica/psicologia , Fator de Necrose Tumoral alfa/metabolismo , Animais , Anticorpos Monoclonais/farmacologia , Anticorpos Neutralizantes/farmacologia , Ansiedade/metabolismo , Ansiedade/fisiopatologia , Dor Crônica/induzido quimicamente , Dor Crônica/imunologia , Comportamento Exploratório , Adjuvante de Freund , Técnicas In Vitro , Inflamação/induzido quimicamente , Inflamação/imunologia , Inflamação/fisiopatologia , Infliximab , Masculino , Aprendizagem em Labirinto , Camundongos , Camundongos Endogâmicos C57BL , Transmissão Sináptica , Fator de Necrose Tumoral alfa/imunologia
7.
Clin Exp Metastasis ; 28(8): 765-78, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21785830

RESUMO

Bone is the third most common site of cancer metastasis. Over 30 to 40% of lung cancers can develop skeletal metastasis and no effective curative therapy exists in clinic cases. Previously we screened the different expression of proteins between SBC-5 cells and SBC-3 cells by proteomic study methods (MALDI-TOF/TOF-MS) and found that calcineurin (hereafter referred as Cn) overexpresses in SBC-5 which has special priority in metastasis to bone in a multiple-organ metastasis mice model. However the roles of Cn in osteotropism of SCLC remain to be elucidated. At present study, we decrease CnAα expression in SBC-5 by lentiviral vector-mediated RNAi and found that down regulation of CnAα gene expression can decrease the proliferation and colony formation rate, impede the cell cycle progression, reduce the cell migration and invasion, and inhibit cells adhering to bone matrix, but not change the apoptosis rate of SBC-5 in vitro. In vivo down or up regulation of CnAα gene expression can only decrease or increase the bone metastasis rate, but not affect the metastasis rate to the visceral organs. Our research reveals that CnAα is closely related to the osteotropism metastasis of SCLC and a candidate tumor promotor gene for developing bone metastases.


Assuntos
Neoplasias Ósseas/secundário , Calcineurina/metabolismo , Lentivirus/genética , Neoplasias Pulmonares/patologia , RNA Interferente Pequeno/genética , Carcinoma de Pequenas Células do Pulmão/patologia , Animais , Apoptose , Sequência de Bases , Western Blotting , Neoplasias Ósseas/genética , Neoplasias Ósseas/metabolismo , Calcineurina/genética , Inibidores de Calcineurina , Adesão Celular , Diferenciação Celular , Movimento Celular , Proliferação de Células , Regulação para Baixo , Feminino , Citometria de Fluxo , Vetores Genéticos/administração & dosagem , Humanos , Técnicas Imunoenzimáticas , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos NOD , Camundongos SCID , Dados de Sequência Molecular , RNA Mensageiro/genética , Reação em Cadeia da Polimerase em Tempo Real , Carcinoma de Pequenas Células do Pulmão/genética , Carcinoma de Pequenas Células do Pulmão/metabolismo , Células Tumorais Cultivadas
8.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi ; 19(5): 465-6, 2003 Sep.
Artigo em Zh | MEDLINE | ID: mdl-15169658

RESUMO

AIM: To study the relationship between expression of bladder cancer-associated protein (BLCAP) and malignancy of osteosarcoma. METHODS: SABC method was applied to study the expression of BLCAP protein in osteosarcoma, according to clinical results, to analyze the prognosis value of BLCAP protein in osteosarcoma. RESULTS: The positive rate of BLCAP protein in primary osteosarcoma was 65.6%,much higher than that in recurrent osteosarcoma, which was 25.0%. CONCLUSION: It may be helpful for evaluating the prognosis of osteosarcoma to study the relationship between expression of BLCAP protein and malignancy of osteosarcoma.


Assuntos
Neoplasias Ósseas/química , Proteínas de Neoplasias/análise , Osteossarcoma/química , Neoplasias Ósseas/patologia , Humanos , Imuno-Histoquímica , Invasividade Neoplásica , Proteínas de Neoplasias/genética , Osteossarcoma/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA